Abstract:Background Clinical outcomes of patients with glioma are still poor, even after standard treatments, including surgery combined with radiotherapy and chemotherapy. New therapeutic strategies and targets for glioma are urgently needed. Plasminogen activator urokinase receptor (PLAUR), a highly glycosylated integral membrane protein, is reported to modulate plasminogen activation and extracellular matrix degradation in many malignant cancers, but its role in gliomas remains unclear.Methods Glioma samples with mRNA sequencing data and clinical information from the Chinese Glioma Genome Atlas (n = 310) data set and The Cancer Genome Atlas (n = 611) data set were collected for this study. Analyses using Kaplan-Meier plots, time-dependent receiver operating characteristic curves, Cox regression, and nomograms were conducted to evaluate the prognostic performance of PLAUR expression. Analyses using Metascape, ESTIMATE, EPIC, and immunohistochemical staining were performed to reveal the potential biological mechanism. The statistical analysis and graphical work were completed using SPSS, R language, and GraphPad Prism.Results PLAUR was highly expressed in phenotypes associated with glioma malignancy and could serve as an independent prognostic indicator. Functional analysis revealed the correlation between PLAUR and immune response. Further studies found that samples with higher PLAUR expression were infiltrated with fewer CD8 T cells and many more M2 macrophages. Strong positive correlation was demonstrated between PLAUR expression and some immunosuppressive markers, including immune checkpoints and cytokines. These findings were also confirmed in patient samples.Conclusion Our results elucidated the clinical significance and immunosuppressive effect of PLAUR in gliomas, which might provide some clues in glioma immunotherapy.Implications for Practice Although the efficacy of immunotherapy has been verified in other tumors, its application in glioma is impeded because of the unique microenvironment. Tumor-associated macrophages, which are particularly abundant in a glioma mass, contribute much to the immunosuppressive microenvironment and offer new opportunities in glioma immunotherapy. The results of this study identified plasminogen activator urokinase receptor (PLAUR) expression as a potential marker to predict the infiltration of macrophages and the status of immune microenvironment in patients with glioma, suggesting that treatment decisions could be based on PLAUR level when administering immunotherapeutics. The soluble PLAUR in blood and other body fluids would make this approach easy to implement in the clinic.

Comprehensive Analysis of the Importance of PLAUR in the Progression and Immune Microenvironment of Renal Clear Cell Carcinoma

Combination of Theoretical Analysis and Experiments: Exploring the Role of PLA2G7 in Human Cancers, Including Renal Cancer

Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features And Acts As An Unfavorable Prognostic Biomarker In Glioma

Pan-cancer Analysis of PLAU Indicates Its Potential Prognostic Value and Correlation with Neutrophil Infiltration in BLCA.

Overexpressed PLAU and Its Potential Prognostic Value in Head and Neck Squamous Cell Carcinoma.

PLAU Promotes Cell Proliferation and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma

Integration Analysis of PLAUR As a Sunitinib Resistance and Macrophage Related Biomarker in Ccrcc, an in Silicon and Experimental Study.

PLAU contributes to the development of cholangiocarcinoma via activating NF‐κB signaling pathway

A Novel Defined PANoptosis-Related Mirna Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A Mirna Signature for the Prognosis of Ccrcc

Prognostic Roles of Phosphofructokinase Platelet in Clear Cell Renal Cell Carcinoma and Correlation with Immune Infiltration

Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma

Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma

Prognostic Significance and Gene Co-Expression Network of <i>PLAU</i> and <i>PLAUR</i> in Gliomas

Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation

PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-κB/IL8 pathway

Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma.

Identifying PLAUR as a Pivotal Gene of Tumor Microenvironment and Regulating Mesenchymal Phenotype of Glioblastoma

The expression, prognostic value and potential mechanism of PLCB2 in clear cell renal cell carcinoma

Hypomethylation and downregulation of miR-23b-3p are associated with upregulated PLAU: a diagnostic and prognostic biomarker in head and neck squamous cell carcinoma

AURKB promotes immunogenicity and immune infiltration in clear cell renal cell carcinoma

LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer